Jeff Aronin, A Leader In Innovative Healthcare Solutions

Jeff Aronin began his illustrious career at DePaul University, where he earned his Bachelor of Science degree. He then went on to earn a Masters in Business Administration from Northern Illinois University.


In 2010, Aronin’s talented leadership skills led him to his present leadership role as CEO and chairman of Paragon Biosciences, LLC. This life sciences company is innovation based and deals with finances, accelerates and development of new companies that invent life changing advancements in biotechnology to improve the care of patients. The company’s focus is finding ways to help patients that suffer from diseases that are debilitating and offer no effective treatments. Jeff Aronin along with his team have gotten thirteen Novel Drug Approvals sanctioned by the FDA.


In 2017, Aronin was recognized by The Weizmann Institute Leadership Award recipient for his dedication to improving the lives of others by delivering the hope and promise of science and new therapy options to patients who need them. This award is given annually to a dedicated medical professional.


Jeff Aronin also serves as chair of NEXT’s bioscience committee which is based in Chicago. At NEXT, Aronin lead the way in the development of MATTER, a health technology center where he serves as co-chairman and founder initiating a major philanthropic innovation success story that includes 200 plus companies established and grown in the past five years.


Jeff Aronin serves or has served on several boards including the Chicago’s Museum of Science and Industry, Discover Financial Services, The Ravinia Music Festival and the medical center at the University of Chicago.


Recently, Aronin was recognized by Insights Care magazine as one of the top 20 most influential professional leaders in healthcare for 2018. He was sighted for his keen ability to help bring drugs that are life altering to patients who need them and for his vision that brought over 32 New Drug and Noval approved that were earned y research and development team at Paragon.